{"filings":[{"id":1085919,"accession_number":"0001193125-26-272814","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2026-06-16T21:00:17+00:00","items":["5.07"],"status":"ready","headline":"All 9 resolutions pass at Silence Therapeutics 2026 AGM including director re-elections and say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Both director nominees re-elected: Rhonda Hellums (47.2M for, 5.6M against) and James Ede-Golightly (52.1M for, 0.6M against).","Advisory say-on-pay approved with 48.2M votes for, 73.7K against, and 4.4M abstentions.","Ratification of PricewaterhouseCoopers as US and UK auditors passed with ~52.7M votes for.","Directors' remuneration report for 2025 approved: 48.3M for, 66.5K against, 4.4M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982236,"accession_number":"0001193125-26-266705","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2026-06-11T11:35:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Silence Therapeutics reports durable phlebotomy reduction and QoL gains from Phase 1 divesiran study at EHA 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.","Median time to first phlebotomy was 287 days among 14 evaluable patients.","Majority had improved MPN-10 symptom scores through Week 34, indicating better quality of life.","Phase 2 SANRECO (Q6W and Q12W dosing) topline results expected August 2026.","Divesiran well tolerated; mild injection-site reactions, no treatment-related SAEs or discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501240,"accession_number":"0001193125-26-229089","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2026-05-18T21:00:15+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.","Jefferies receives 3.0% commission on gross proceeds; no minimum obligation to sell ADSs.","After further tax analysis, company believes it was not a PFIC for FY 2025 (previously disclosed potential PFIC status).","Added risk factor noting PFIC classification is fact-intensive and could change; no assurance from IRS.","Legal opinion from Cooley (UK) LLP on ADS validity filed as exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93097,"accession_number":"0001193125-26-210428","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.","Cash, cash equivalents & short-term investments at $70.1M as of March 31, 2026.","R&D expenses fell to $9.1M from $20.8M, primarily due to zerlasiran Phase 3 readiness completed in 2025.","Phase 2 SANRECO trial of divesiran for polycythemia vera ongoing; topline results expected August 2026.","Phase 1 abstracts for divesiran (EHA) and SLN312/AZD1705 (EAS) accepted for upcoming congress presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":422000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104438,"accession_number":"0001193125-26-092578","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.","Collaboration revenue dropped to $0.6M from $43.3M; R&D spend flat at $67.8M.","Cash and investments $85.1M as of Dec 31, 2025; key Phase 2 SANRECO topline due Q3 2026.","AstraZeneca will not develop SLN312 beyond Phase 1; Silence regains global rights.","CEO search underway after former CEO departure in Dec 2025; Iain Ross interim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120732,"accession_number":"0001193125-25-327575","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Silence Therapeutics appoints CFO Rhonda Hellums to Board of Directors effective Dec 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rhonda Hellums, EVP and CFO, appointed as executive director effective December 18, 2025.","Her initial term runs until the 2026 Annual General Meeting of Shareholders.","Ms. Hellums will not receive additional compensation for board service.","She will not serve on any board committee.","No family relationships or material transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120728,"accession_number":"0001193125-25-328684","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K/A","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Silence Therapeutics discloses interim CEO pay and new director committee roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.","New director James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees; granted 90,000 option shares vesting over 12 months.","Ross is also eligible for a discretionary cash bonus as determined by the Remuneration Committee.","Both option grants are under the company's 2023 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120731,"accession_number":"0001193125-25-319156","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Silence Therapeutics CEO Craig Tooman departs by mutual consent; Chairman Iain Ross named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.","Chairman Iain Ross appointed as interim principal executive officer effective immediately.","James Ede-Golightly re-appointed to Board; previously served as Non-Executive Director from 2019 to June 2025.","Company expects to add a US-based Board member in due course."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120730,"accession_number":"0001193125-25-268102","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silence Therapeutics Q3 2025 net loss $21M; divesiran Phase 2 fully enrolled with topline data in 3Q 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.","Net loss $21.0M for Q3 2025 vs $35.5M in Q3 2024, primarily due to lower foreign currency loss.","SANRECO Phase 2 study of divesiran in polycythemia vera fully enrolled (48 patients); topline results expected Q3 2026.","R&D expenses $20.5M (vs $20.2M YoY); G&A expenses $5.8M (vs $7.7M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":525000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120729,"accession_number":"0001193125-25-247692","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","2.02","9.01"],"status":"ready","headline":"Silence Therapeutics completes SANRECO Phase 2 enrollment for divesiran in PV; topline data expected 3Q'26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.","Primary endpoint: proportion maintaining HCT <45% without phlebotomies between weeks 18 and 36.","Phase 2 evaluates two dosing intervals (Q6W and Q12W); Phase 1 showed potential with Q6W dosing.","Topline results anticipated in the third quarter of 2026.","CEO cites divesiran as first-in-class siRNA targeting TMPRSS6 for significant unmet need in PV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137317,"accession_number":"0001193125-25-180313","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Michael Davidson resigns from Silence Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.","He also stepped down from Audit, Risk, Remuneration, and Science & Technology Committees.","Board reduced from five to four members; Iain Ross appointed to Audit and Risk Committee.","Davidson remains CEO of NewAmsterdam Pharma; resignation not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137316,"accession_number":"0001193125-25-174958","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.","Cash and short-term investments $114.2M as of June 30, 2025; expected to fund operations into 2028.","Divesiran Phase 2 SANRECO trial >50% enrolled; on track for full enrollment by year-end 2025.","Paused Phase 1 initiation of SLN548 to prioritize extra-hepatic siRNA targeting; preclinical data promising.","Zerlasiran Phase 3 readiness activities completed; seeking partnership for Phase 3 and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":366000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154635,"accession_number":"0001193125-25-149704","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silence Therapeutics shareholders approve all 13 AGM resolutions, re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All directors re-elected: David Lemus (77.0M for), Tim McInerney (77.0M for), Iain Ross (74.8M for), Craig Tooman (78.2M for).","Advisory say-on-pay resolution passed with 70.8M for vs 3.1M against.","PwC ratified as US auditor with 78.3M for; 2024 UK accounts adopted with 78.2M for.","Shareholders voted 77.7M in favor of annual frequency for advisory say-on-pay votes.","Special resolution to adopt new articles of association passed with 72.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154634,"accession_number":"0001193125-25-115533","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.","Net loss $28.5M ($0.20/ADS) vs $2.3M ($0.02) in Q1 2024; R&D up $9.0M to $20.8M.","Divesiran Phase 2 SANRECO enrollment on track to complete by year-end 2025; EHA presentation June 12-15.","Cost savings initiatives implemented to extend cash guidance into 2028; Phase 3 readiness for zerlasiran ongoing.","Appointed Tim McInerney to Board of Directors effective May 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":142000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154633,"accession_number":"0001193125-25-113364","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Silence Therapeutics appoints Tim McInerney to board; James Ede-Golightly to retire at June 2025 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim McInerney appointed director effective May 5, 2025; will chair Remuneration Committee and join Audit and Risk Committee.","James Ede-Golightly to retire at end of his term at 2025 AGM (June 26); steps down as Remuneration Committee chair immediately.","McInerney receives $56,000 annual retainer, initial option for 48,000 ordinary shares (36-month monthly vest), and annual grant of same.","McInerney brings 30+ years pharma/healthcare investment banking and executive experience; served on boards of Emisphere, Insite Vision, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173161,"accession_number":"0001193125-25-039248","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.","Cash, cash equivalents and short-term investments of $147.3M at Dec 31, 2024.","Collaboration revenue $43.1M (up $12.2M YoY); R&D expenses $67.9M (up $11M).","Zerlasiran Phase 3 CVOT will not start without a partner; cash guidance extended into 2027.","Divesiran Phase 2 PV enrollment expected to complete by end-2025; Hansoh Pharma exited collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":43258000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173160,"accession_number":"0001193125-25-000144","cik":1479615,"company_name":"Silence Therapeutics plc","ticker":"SLN","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Silence Therapeutics loses foreign private issuer status, will file as U.S. domestic issuer from Jan 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Effective January 1, 2025, Silence Therapeutics (SLN) will file periodic reports on U.S. domestic issuer forms, no longer as a foreign private issuer.","Domestic issuer filings are more detailed and extensive, and must be filed more promptly than foreign private issuer forms.","Company announced it will disseminate material information via press releases, its website, investor relations page, LinkedIn, and X account.","No other material business or financial updates were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":313637814.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}